Literature DB >> 2277194

General principles of therapy of pyogenic meningitis.

M G Täuber1, M A Sande.   

Abstract

In bacterial meningitis, several pharmacodynamic factors determine therapeutic success-when defined as sterilization of the CSF: (1) Local host defense deficits in the CNS require the use of bactericidal antibiotics to sterilize the CSF. (2) CSF antibiotic concentrations that are at least 10-fold above the MBC are necessary for maximal bactericidal activity. Protein binding, low pH, and slow bacterial growth rates are among the factors that may explain the high antibiotic concentrations necessary in vivo. (3) High CSF peak concentrations that lead to rapid bacterial killing appear more important than prolonged suprainhibitory concentrations, probably because very low residual levels in the CSF prevent bacterial regrowth, even during relatively long dosing intervals. (4) Penetration of antibiotics into the CSF is significantly impaired by the blood-brain barrier and thus, very high serum levels are necessary to achieve the CSF concentrations required for optimal bactericidal activity. Beyond these principles, recent data suggests that rapid lytic killing of bacteria in the CSF may have harmful effects on the brain because of the release of biologically active products from the lysed bacteria. Since rapid CSF sterilization remains a key therapeutic goal, the harmful consequences of bacterial lysis present a major challenge in the therapy of bacterial meningitis. Currently, dexamethasone represents that only clinically beneficial approach to reduce the harmful effects of bacterial lysis, and novel approaches are required to improve the outcome of this serious infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2277194

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  10 in total

1.  Penetration of rufloxacin into the cerebrospinal fluid in patients with inflamed and uninflamed meninges.

Authors:  M V Moretti; S Pauluzzi; M Cesana
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

Review 2.  Diagnosis and treatment of bacterial meningitis.

Authors:  H El Bashir; M Laundy; R Booy
Journal:  Arch Dis Child       Date:  2003-07       Impact factor: 3.791

3.  Use of corticosteroids and other adjunct therapies for acute bacterial meningitis in adults.

Authors:  Kameshwar Prasad; Nirendra Kumar Rai; Amit Kumar
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

Review 4.  Bacterial meningitis: current controversies in approaches to treatment.

Authors:  A J Williams; S Nadel
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  Antimicrobial pharmacokinetics in endophthalmitis treatment: studies of ceftazidime.

Authors:  T A Meredith
Journal:  Trans Am Ophthalmol Soc       Date:  1993

Review 6.  Bacterial meningitis. Practical guidelines for management.

Authors:  J Rockowitz; A R Tunkel
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

7.  Use of ampicillin-sulbactam for treatment of experimental meningitis caused by a beta-lactamase-producing strain of Escherichia coli K-1.

Authors:  L Guerra-Romero; S L Kennedy; M A Fournier; J H Tureen; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

8.  beta-Lactamase-mediated inactivation and efficacy of cefazolin and cefmetazole in Staphylococcus aureus abscesses.

Authors:  M T Fields; B L Herndon; D M Bamberger
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

Review 9.  Cefpirome clinical pharmacokinetics.

Authors:  L C Strenkoski; D E Nix
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

10.  Kinetics of ofloxacin and its metabolites in cerebrospinal fluid after a single intravenous infusion of 400 milligrams of ofloxacin.

Authors:  R Nau; M Kinzig; T Dreyhaupt; H Kolenda; F Sörgel; H W Prange
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.